Targeting 3CLPRO and SARS-COV-2 RDRP by amphimedon sp. Metabolites: A computational study

N/ACitations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Since December 2019, novel coronavirus disease 2019 (COVID-19) pandemic has caused tremendous economic loss and serious health problems worldwide. In this study, we investigated 14 natural compounds isolated from Amphimedon sp. via a molecular docking study, to examine their ability to act as anti-COVID-19 agents. Moreover, the pharmacokinetic properties of the most promising compounds were studied. The docking study showed that virtually screened compounds were effective against the new coronavirus via dual inhibition of SARS-CoV-2 RdRp and the 3CL main protease. In particular, nakinadine B (1), 20-hepacosenoic acid (11) and amphimedoside C (12) were the most promising compounds, as they demonstrated good interactions with the pockets of both enzymes. Based on the analysis of the molecular docking results, compounds 1 and 12 were selected for molecular dynamics simulation studies. Our results showed Amphimedon sp. to be a rich source for anti-COVID-19 metabolites.

Cite

CITATION STYLE

APA

Shady, N. H., Hayallah, A. M., Mohamed, M. F. A., Ghoneim, M. M., Chilingaryan, G., Al-Sanea, M. M., … Abdelmohsen, U. R. (2021). Targeting 3CLPRO and SARS-COV-2 RDRP by amphimedon sp. Metabolites: A computational study. Molecules, 26(12). https://doi.org/10.3390/molecules26123775

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free